Novel amylomacins from seaweed-associated Bacillus amyloliquefaciens as prospective antimicrobial leads attenuating resistant bacteria
- 19 October 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in World Journal of Microbiology and Biotechnology
- Vol. 37 (12), 1-12
- https://doi.org/10.1007/s11274-021-03161-9
Abstract
The rise in antibiotic-resistant bacterial strains prompting nosocomial infections drives the search for new bioactive substances of promising antibacterial properties. The surfaces of seaweeds are rich in heterotrophic bacteria with prospective antimicrobial substances. This study aimed to isolate antibacterial leads from a seaweed-associated bacterium. Heterotrophic Bacillus amyloliquefaciens MTCC 12716 associated with the seaweed Hypnea valentiae, was isolated and screened for antimicrobial properties against drug-resistant pathogens. The bacterial crude extract was purified and three novel amicoumacin-class of isocoumarin analogues, 11′-butyl acetate amicoumacin C (amylomacin A), 4′-hydroxy-11′-methoxyethyl carboxylate amicoumacin C (amylomacin B) and 11′-butyl amicoumacin C (amylomacin C) were isolated to homogeneity. The studied amylomacins possessed potential activities against Pseudomonas aeruginosa, vancomycin-resistant Enterococcus faecalis, Klebsiella pneumoniae, methicillin-resistant Staphylococcus aureus, and Shigella flexneri with a range of minimum inhibitory concentration values from 0.78 to 3.12 µg/mL, although standard antibiotics ampicillin and chloramphenicol were active at 6.25–25 µg/mL. Noticeably, the amylomacin compound encompassing 4′-hydroxy-11′-methoxyethyl carboxylate amicoumacin C functionality (amylomacin B), displayed considerably greater antagonistic activities against methicillin-resistant S. aureus, vancomycin-resistant E. faecalis, Vibrio parahaemolyticus, Escherichia coli, and K. pneumoniae (minimum inhibitory concentration 0.78 μg/mL) compared to the positive controls and other amylomacin analogues. Antimicrobial properties of the amylomacins, coupled with the presence of polyketide synthase-I/non-ribosomal peptide synthetase hybrid gene attributed the bacterium as a promising source of antimicrobial compounds with pharmaceutical and biotechnological applications. Graphic abstractKeywords
Funding Information
- Indian Council of Agricultural Research (MBT/HLT/SUB23)
- Kerala State Council for Science, Technology and Environment (040/FSHP-LSS/2014/KSCSTE)
This publication has 30 references indexed in Scilit:
- Five New Amicoumacins Isolated from a Marine-Derived Bacterium Bacillus subtilisMarine Drugs, 2012
- Development of Marine ProbioticsPublished by Elsevier BV ,2012
- Jania rubens-associated bacteria: molecular identification and antimicrobial activityJournal of Applied Phycology, 2011
- Isolation, Taxonomy, and Antagonistic Properties of Halophilic Actinomycetes in Saharan Soils of AlgeriaApplied and Environmental Microbiology, 2011
- Seasonal dynamics of bacterial biofilms on the kelp Laminaria hyperboreaAquatic Microbial Ecology, 2010
- Genetic analysis of xenocoumacin antibiotic production in the mutualistic bacterium Xenorhabdus nematophilaMolecular Microbiology, 2009
- Bacilosarcins A and B, novel bioactive isocoumarins with unusual heterocyclic cores from the marine-derived bacterium Bacillus subtilisTetrahedron, 2008
- Phylogenetic analysis of type I polyketide synthase and nonribosomal peptide synthetase genes in Antarctic sedimentExtremophiles, 2007
- Marine Microorganisms as a Source of New Natural ProductsAdvances in Applied Microbiology, 1997
- Antibiotic activity of epiphytic bacteria isolated from intertidal seaweedsMicrobial Ecology, 1985